Avalyn Pharma filed for an initial public offering as a pulmonary fibrosis biotech developing inhaled formulations of approved oral medicines. The company’s filing signals it is seeking public-market capital to fund late-stage development, with a focus on delivering therapies directly to the lung. The IPO move comes as pulmonary fibrosis remains an area of heavy unmet need and as inhaled drug delivery becomes a key differentiator for improving tolerability and systemic exposure. Avalyn’s approach, using inhaled delivery based on already-approved pills, is designed to translate an established therapeutic rationale into a new administration route. Industry professionals will be watching for details on the amount raised, underwriting, and the clinical readouts that the company intends to support post-listing. The filing also reflects an ongoing willingness among investors to fund programs with clearer scientific linkage to existing standards of care, especially when delivery innovation could broaden differentiation in a crowded IPF landscape.